Low increase in serum lipids in patients receiving a combination of ritonavir, saquinavir and efavirenz.
Piketty
C
C
Service d'Immunologie Clinique, Hôpital Européen Georges Pompidou and Université Pierre et Marie Curie, Paris, France. christophe.piketty@hop.egp.ap-hop.paris.fr
Peytavin
G
G
Trylezinski
A
A
Gonzalez-Canali
G
G
Castiel
P
P
Weiss
L
L
Kazatchkine
M D
MD
D000480:Alkynes; D048588:Benzoxazines; D001786:Blood Glucose / Q000187:drug effects; D002784:Cholesterol / Q000097:blood*; D003521:Cyclopropanes; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D010078:Oxazines / Q000097:blood / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000097:blood / Q000627:therapeutic use*; D019438:Ritonavir / Q000097:blood / Q000627:therapeutic use; D019258:Saquinavir / Q000097:blood / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood*
D000480:Alkynes; D048588:Benzoxazines; D001786:Blood Glucose; D003521:Cyclopropanes; D017320:HIV Protease Inhibitors; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D014280:Triglycerides; D002784:Cholesterol; C098320:efavirenz; D019258:Saquinavir; D019438:Ritonavir